Infinity Pharma (INFI) – StreetInsider.com Reports
-
Infinity Pharma (INFI) Announces Value Preservation and Maximization Plan
-
Infinity Pharma (INFI) Announces Termination of Merger Agreement with MEI Pharma (MEIP)
-
Infinity Pharma (INFI) Announces Shareholder Approval of Merger with MEI Pharma
-
ISS Recommends Infinity Pharmaceuticals (INFI) Stockholders Vote FOR the Merger with MEI Pharma, Inc. (MEIP)
-
MEI Pharma (MEIP) Issues Letter to Shareholders
-
Piper Sandler Downgrades Infinity Pharmaceutical (INFI) to Neutral
-
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33%
-
MEI Pharma (MEIP) and Infinity Pharmaceuticals (INFI) Announce Merger Agreement
-
Infinity Pharma (INFI) halted, news pending
-
B.Riley Downgrades Infinity Pharmaceutical (INFI) to Neutral
-
Infinity Pharma (INFI) Provides MARIO-3 Update
-
Jones Trading Downgrades Infinity Pharmaceutical (INFI) to Hold
-
Infinity Pharmaceutical (INFI) PT Lowered to $3 at Piper Sandler
-
Infinity Pharma (INFI) Misses Q1 EPS by 1c
-
Infinity Pharmaceutical (INFI) PT Slashed to $4 at Truist Securities, Continues to Sees Substantial Potential Upside but Cites Cash Overhang
-
Infinity Pharmaceutical (INFI) PT Lowered to $7 at Oppenheimer
-
Infinity Pharmaceutical (INFI) PT Lowered to $4 at Piper Sandler
-
Infinity Pharmaceutical (INFI) PT Lowered to $5 at B.Riley
-
Infinity Pharma (INFI) Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
-
Infinity Pharmaceutical (INFI) PT Raised to $7 at B.Riley
-
Infinity Pharma (INFI) Added to NASDAQ Biotechnology Index
-
Infinity Pharma (INFI) Presents Encouraging Phase 2 MARIO-3 TNBC Trial Data
-
Infinity Pharma (INFI) Tops Q3 EPS by 1c
-
Pre-Open Stock Movers 10/18: (ADMP) (OYST) (INFI) Higher; (RVNC) (OMER) (MNKD) Lower (more...)
-
UPDATE: H.C. Wainwright Starts Infinity Pharmaceutical (INFI) at Buy
-
Infinity Pharma (INFI) Appoints Robert Ilaria as Chief Medical Officer; Brian Schwartz to its Board
-
Pre-Open Stock Movers 08/02: (XCUR) (DLPN) (AUTL) Higher; (PH) (SQ) Lower (more...)
-
UPDATE: JPMorgan Upgrades Infinity Pharmaceutical (INFI) to Overweight
-
Increasing unusual call option volume: INFI SPRT WSM EGHT ADNT UP CSTM
-
Wells Fargo Upgrades Infinity Pharmaceutical (INFI) to Overweight, Sees Upside to $30
-
Pre-Open Stock Movers 07/28: (INFI) (BTBT) (LKFN) Higher; (TDOC) (CSGP) (SPOT) Lower (more...)
-
Infinity Pharmaceutical (INFI) PT Raised to $8 at Piper Sandler
-
Infinity Pharmaceutical (INFI) PT Lowered to $4 at B.Riley
-
Infinity Pharmaceutical (INFI) Trading 'Nearly at Cash' Despite Drug that Works - Truist Securities
-
Infinity Pharma (INFI) Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer and Phase 2 MARIO-3 Trial in TNBC
-
Infinity Pharma (INFI) call put ratio 14 calls to 1 put into data
-
Infinity Pharma (INFI) August IV bid above October into data
-
Infinity Pharma (INFI) IV into updates
-
Infinity Pharma (INFI) call put ratio 2.5 calls to 1 put into data
-
Infinity Pharma (INFI) option volume up into data
-
Infinity Pharma (INFI) call put ratio 8.7 calls to 1 put with focus on August 2 and 3 calls into update
-
What To Expect Ahead Of Infinity Pharmaceuticals, Inc’s (INFI) 1L TNBC Data Update on July 27th?
-
UPDATE: B.Riley Assumes Infinity Pharmaceutical (INFI) at Buy
-
Companies with NDRs 7/06
-
Infinity Pharma (INFI) Misses Q1 EPS by 3c, Revenues Miss
-
Pre-Open Stock Movers 03/18: (UPST) (TKAT) (SINO) Higher; (TBIO) (CFRX) (RIDE) Lower (more...)
-
Truist Securities Starts Infinity Pharmaceutical (INFI) at Buy; $12 PT
-
Infinity Pharmaceutical (INFI) PT Raised to $4 at Wells Fargo
-
Piper Sandler Starts Infinity Pharmaceutical (INFI) at Overweight
-
Infinity Pharma (INFI) Prices 21M Share Common Offering at $3.80/Sh
Back to INFI Stock Lookup